Under the terms of the agreement, Aptamer Group will develop Optimer ligands to be integrated into its partner’s life science research platform. The deal structure includes phased project payments potentially totalling multiple millions of pounds, with IP-related milestone payments and long-term single-digit royalty payments.
Optimer ligands are nucleic acid-based affinity ligands that can be used as an antibody alternative to enable novel solutions across the life sciences. The Optimer platform consists of three parallel discovery processes that are optimised for specific target types from small molecules to proteins and cells, for increased success in the discovery and development of high affinity, high specificity Optimer ligands.
For the full story, please visit the Aptamer Group website.